Recombinant Cynomolgus TGFBR2, Fc tagged

• Cat.No.: TGFBR2-8814C
• Product Overview: Recombinant Cynomolgus TGFBR2 (F6Q1B1) (Met1-Arg159), fused with the Fc region of human IgG1 at the C-terminus, was produced in Human Cell.

Specification

• Source: Human Cells
• Species: Cynomolgus
• Tag: Fc
• Form: Lyophilized from a 0.2μm filtered solution of PBS, pH 7.4
• Molecular Mass: The recombinant cynomolgus TGFBR2 is a disulfide-linked homodimer. The reduced monomer comprises 377 amino acids and has a calculated molecular mass of 42.4 KDa.The apparent molecular mass of cynomolgus CD38 is approximately 56-62 KDa respectively in SDS-PAGE.
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Stability: Samples are stable for up to twelve months from date of receipt at -70oC.
• Storage: Store it under sterile conditions at -20oC~-70oC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4℃ before opening to recover the entire contents.
• Protein length: Met1-Arg159

Gene Information

• Gene Name: TGFBR2 transforming growth factor, beta receptor II (70/80kDa) [ Macaca fascicularis (crab-eating macaque) ]
• Official Symbol: TGFBR2
• Gene ID: 102134273
• mRNA Refseq: XM_005545565
• Protein Refseq: XP_005545622

Reviews

04/14/2023

TGFBR2 protein's remarkable performance in ELISA and protein electron microscopy structure analysis positions it as a valuable tool in various fields, including cardiovascular research, developmental biology, and molecular medicine.

12/13/2022

TGFBR2 protein's utility extends to protein electron microscopy structure analysis, where it plays a crucial role in investigating the detailed architecture and conformational changes of proteins.

06/25/2021

TGFBR2 protein is highly recommended for use in various research applications, including ELISA and protein electron microscopy structure analysis.

Q&As

How is TGFBR2 linked to autoimmune diseases?

Dysregulation of TGF-beta signaling, including TGFBR2, has been associated with autoimmune diseases. Understanding these pathways may provide insights into developing targeted therapies.

Are there clinical trials targeting TGFBR2?

Yes, there are ongoing clinical trials exploring the modulation of TGFBR2 for various conditions, including cancer and fibrotic diseases.

How does TGFBR2 affect cardiovascular health?

TGFBR2 is involved in cardiovascular development and homeostasis. Dysregulation can contribute to conditions like aortic aneurysms and other cardiovascular diseases.

Is TGFBR2 involved in neurological disorders?

Some studies suggest a potential link between TGFBR2 and neurological disorders. Further research is ongoing to understand its role in conditions like Alzheimer's and Parkinson's disease.

Can TGFBR2 be a therapeutic target for fibrotic diseases?

Yes, TGFBR2 is implicated in fibrosis, and targeting it may offer therapeutic options for diseases characterized by excessive tissue scarring.